| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11337979 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
| US11464778 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
| US11759468 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
Liqrev is owned by Cmp Dev Llc.
Liqrev contains Sildenafil Citrate.
Liqrev has a total of 3 drug patents out of which 0 drug patents have expired.
Liqrev was authorised for market use on 28 April, 2023.
Liqrev is available in suspension;oral dosage forms.
Liqrev can be used as liqrev is indicated for the treatment of pulmonary arterial hypertension (who group 1) in adults to improve exercise ability and delay clinical worsening.
The generics of Liqrev are possible to be released after 24 December, 2038.
Drugs and Companies using SILDENAFIL CITRATE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Liqrev is indicated for the treatment of pulmonary arterial hypertension (who group 1) in adults to improve exercise ability and delay clinical worsening
Dosage: SUSPENSION;ORAL
LIQREV family patents
